Literature DB >> 1320365

Activities of the four optical isomers of 2',3'-dideoxy-3'-thiacytidine (BCH-189) against human immunodeficiency virus type 1 in human lymphocytes.

R F Schinazi1, C K Chu, A Peck, A McMillan, R Mathis, D Cannon, L S Jeong, J W Beach, W B Choi, S Yeola.   

Abstract

Four different isomers of 2',3'-dideoxy-3'-thiacytidine [beta-DL-(+-)-BCH-189] were evaluated in primary human lymphocytes infected with human immunodeficiency virus type 1. The beta-L-(-) isomer was the most potent enantiomer, with a median effective concentration of 1.8 nM and no discernible cytotoxicity up to 100 microM. The relative order of potencies for the isomers was beta-L-(-) greater than beta-DL-(+-) racemic greater than beta-D-(+) greater than alpha-L-(+) greater than alpha-D-(-). The beta-L-(-) enantiomer was as potent as 3'-azido-3'-deoxythymidine.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1320365      PMCID: PMC190578          DOI: 10.1128/AAC.36.3.672

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  14 in total

1.  The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro.

Authors:  J A Coates; N Cammack; H J Jenkinson; I M Mutton; B A Pearson; R Storer; J M Cameron; C R Penn
Journal:  Antimicrob Agents Chemother       Date:  1992-01       Impact factor: 5.191

2.  Selective inhibition of human immunodeficiency virus type 1 replication by the (-) but not the (+) enantiomer of gossypol.

Authors:  T S Lin; R Schinazi; B P Griffith; E M August; B F Eriksson; D K Zheng; L A Huang; W H Prusoff
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

3.  Combinations of isoprinosine and 3'-azido-3'-deoxythymidine in lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; D L Cannon; B H Arnold; D Martino-Saltzman
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

4.  Activities of 3'-azido-3'-deoxythymidine nucleotide dimers in primary lymphocytes infected with human immunodeficiency virus type 1.

Authors:  R F Schinazi; J P Sommadossi; V Saalmann; D L Cannon; M Y Xie; G C Hart; G A Smith; E F Hahn
Journal:  Antimicrob Agents Chemother       Date:  1990-06       Impact factor: 5.191

Review 5.  Targeted therapy of human immunodeficiency virus-related disease.

Authors:  H Mitsuya; R Yarchoan; S Kageyama; S Broder
Journal:  FASEB J       Date:  1991-07       Impact factor: 5.191

6.  Potent and selective activity of a new carbocyclic nucleoside analog (carbovir: NSC 614846) against human immunodeficiency virus in vitro.

Authors:  R Vince; M Hua; J Brownell; S Daluge; F C Lee; W M Shannon; G C Lavelle; J Qualls; O S Weislow; R Kiser
Journal:  Biochem Biophys Res Commun       Date:  1988-10-31       Impact factor: 3.575

7.  Resolution of racemic carbovir and selective inhibition of human immunodeficiency virus by the (-) enantiomer.

Authors:  R Vince; J Brownell
Journal:  Biochem Biophys Res Commun       Date:  1990-05-16       Impact factor: 3.575

8.  Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay.

Authors:  B A Larder; B Chesebro; D D Richman
Journal:  Antimicrob Agents Chemother       Date:  1990-03       Impact factor: 5.191

9.  Common evolutionary origin of hepatitis B virus and retroviruses.

Authors:  R H Miller; W S Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1986-04       Impact factor: 11.205

10.  Phosphorylation of 3'-azido-2',3'-dideoxyuridine and preferential inhibition of human and simian immunodeficiency virus reverse transcriptases by its 5'-triphosphate.

Authors:  B F Eriksson; C K Chu; R F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  1989-10       Impact factor: 5.191

View more
  44 in total

1.  Pharmacokinetics of the antiviral agent beta-L-3'-fluoro-2',3'-didehydro-2',3'-dideoxycytidine in rhesus monkeys.

Authors:  Ghazia Asif; Selwyn J Hurwitz; Giuseppe Gumina; Chung K Chu; Harold M McClure; Raymond F Schinazi
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

Review 2.  Antiviral therapy for human immunodeficiency virus infections.

Authors:  E De Clercq
Journal:  Clin Microbiol Rev       Date:  1995-04       Impact factor: 26.132

Review 3.  Mechanisms of nucleoside analog antiviral activity and resistance during human immunodeficiency virus reverse transcription.

Authors:  E J Arts; M A Wainberg
Journal:  Antimicrob Agents Chemother       Date:  1996-03       Impact factor: 5.191

4.  Pharmacokinetics of lamivudine in human immunodeficiency virus-infected patients with renal dysfunction.

Authors:  A E Heald; P H Hsyu; G J Yuen; P Robinson; P Mydlow; J A Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

5.  Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.

Authors:  R F Schinazi; R M Lloyd; M H Nguyen; D L Cannon; A McMillan; N Ilksoy; C K Chu; D C Liotta; H Z Bazmi; J W Mellors
Journal:  Antimicrob Agents Chemother       Date:  1993-04       Impact factor: 5.191

Review 6.  Metabolism and mechanism of antiretroviral action of purine and pyrimidine derivatives.

Authors:  J Balzarini
Journal:  Pharm World Sci       Date:  1994-04-15

7.  Exonuclease removal of dideoxycytidine (zalcitabine) by the human mitochondrial DNA polymerase.

Authors:  Jeremiah W Hanes; Kenneth A Johnson
Journal:  Antimicrob Agents Chemother       Date:  2007-11-05       Impact factor: 5.191

8.  Intracellular nucleotides of (-)-2',3'-deoxy-3'-thiacytidine in peripheral blood mononuclear cells of a patient infected with human immunodeficiency virus.

Authors:  C Solas; Y F Li; M Y Xie; J P Sommadossi; X J Zhou
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

9.  Infectious amplification of wild-type human immunodeficiency virus from patients' lymphocytes and modulation by reverse transcriptase inhibitors in vitro.

Authors:  D Mathez; R F Schinazi; D C Liotta; J Leibowitch
Journal:  Antimicrob Agents Chemother       Date:  1993-10       Impact factor: 5.191

10.  Novel 4'-substituted stavudine analog with improved anti-human immunodeficiency virus activity and decreased cytotoxicity.

Authors:  Ginger E Dutschman; Susan P Grill; Elizabeth A Gullen; Kazuhiro Haraguchi; Shingo Takeda; Hiromichi Tanaka; Masanori Baba; Yung-Chi Cheng
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.